Literature DB >> 12086853

The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.

Stephen L Lessnick1, Caroline S Dacwag, Todd R Golub.   

Abstract

Ewing's sarcoma is associated with a fusion between the EWS and FLI1 genes, forming an EWS/FLI fusion protein. We developed a system for the identification of cooperative mutations in this tumor through expression of EWS/FLI in primary human fibroblasts. Gene expression profiling demonstrated that this system recapitulates many features of Ewing's sarcoma. EWS/FLI-expressing cells underwent growth arrest, suggesting that growth arrest-abrogating collaborative mutations may be required for tumorigenesis. Expression profiling identified transcriptional upregulation of p53, and the growth arrest was rescued by inhibition of p53. These data support a role for p53 as a tumor suppressor in Ewing's sarcoma and demonstrate the use of transcriptional profiling of model systems in the identification of cooperating mutations in human cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086853     DOI: 10.1016/s1535-6108(02)00056-9

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  107 in total

1.  PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.

Authors:  Benjamin Deneen; Scott M Welford; Thu Ho; Felicia Hernandez; Irwin Kurland; Christopher T Denny
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 2.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

3.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

4.  The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.

Authors:  Junhui Zou; Hitoshi Ichikawa; Michael L Blackburn; Hsien-Ming Hu; Anna Zielinska-Kwiatkowska; Qi Mei; Gerald J Roth; Howard A Chansky; Liu Yang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 5.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

6.  Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Authors:  Yoshitaka Miyagawa; Hajime Okita; Hideki Nakaijima; Yasuomi Horiuchi; Ban Sato; Tomoko Taguchi; Masashi Toyoda; Yohko U Katagiri; Junichiro Fujimoto; Jun-Ichi Hata; Akihiro Umezawa; Nobutaka Kiyokawa
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

7.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

8.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

9.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 10.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.